Reactive oxygen species
Reactive oxygen species (ROS) are chemically reactive, oxygen-derived molecules and radicals, including superoxide, hydrogen peroxide, hydroxyl radical, and singlet oxygen.
Reactive oxygen species (ROS) are chemically reactive, oxygen-derived molecules and radicals, including superoxide, hydrogen peroxide, hydroxyl radical, and singlet oxygen. They arise endogenously as byproducts of aerobic metabolism — principally from electron leak at complexes I and III of the mitochondrial respiratory chain — and are also generated deliberately by NADPH oxidases and by peroxisomal and cytochrome P450 reactions. The species interconvert along a defined path: superoxide dismutase converts superoxide to hydrogen peroxide, which is either reduced to water by catalase, glutathione and glutathione peroxidases including Gpx4, and the thioredoxin system, or, in the presence of ferrous iron, converted by Fenton chemistry to the hydroxyl radical. Because they differ in reactivity and diffusion range, hydrogen peroxide acts as a comparatively stable second messenger while the hydroxyl radical reacts near-indiscriminately at its site of formation, and only the antioxidant network standing between them keeps the first from becoming the second.
At physiological levels ROS are signals: they reversibly oxidize cysteine residues on phosphatases, kinases, and transcriptional regulators, shaping proliferation, differentiation, hypoxic adaptation via HIF-1α, and antimicrobial killing by phagocytes. The Nrf2/HO-1 axis is the principal adaptive response, inducing heme oxygenase 1 and related cytoprotective enzymes. When production outstrips clearance, the resulting oxidative stress oxidizes lipids, proteins and nucleic acids, activates NF-κB and the NLRP3 inflammasome with downstream caspase-1 and proinflammatory cytokine release, impairs mitochondrial function, and triggers regulated cell death — notably ferroptosis, in which iron-dependent lipid peroxidation proceeds once Gpx4 activity or glutathione supply is insufficient. These mechanisms underpin the involvement of ROS in diabetes and diabetic wound healing, sepsis and organ injury, drug-induced liver injury, ischemia-reperfusion injury, fibrosis, neurodegeneration including Alzheimer's and Parkinson's disease, and tumor progression within the tumor microenvironment.
The same chemistry is used therapeutically, in both directions. Generating ROS where they are wanted is the effector mechanism of three related modalities: photodynamic therapy excites a photosensitizer with light of a specific wavelength to transfer energy to molecular oxygen, yielding singlet oxygen; sonodynamic therapy uses ultrasound-induced cavitation and related sonochemical processes to generate reactive species, often in the presence of a sonosensitizer; and chemodynamic therapy needs no external energy at all, delivering transition metals that convert the hydrogen peroxide already abundant in tumors into hydroxyl radicals through Fenton or Fenton-like reactions. All three are used against tumor cells and against bacterial biofilms formed by organisms such as Staphylococcus aureus and Escherichia coli, and all three are limited by the glutathione of the target tissue, which motivates paired GSH-depletion strategies. Ionizing radiation kills partly by the same route, through radiolysis of water. Conversely, antioxidant and ROS-scavenging agents, including polyphenols and flavonoids such as kaempferol, are investigated to limit oxidative injury — an approach whose record is mixed, since indiscriminate scavenging removes the signaling species along with the damaging ones. ROS-responsive chemistry — thioketal linkers that cleave in oxidative environments, for example — is meanwhile used to build prodrugs, nanocarriers, hydrogels, and microneedle systems that release drugs such as paclitaxel or doxorubicin selectively where oxidative stress is high.
Where the papers sit
34 papers from the last 6 months study reactive oxygen species directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 2 human data · 31 preclinical · 1 unclassified
Themes 5 themes · 1 paradigm shift
-
ROS-Responsive Nanomedicine
ROS-responsive nanomedicine is moving toward treatment that combines deep-tissue activation, imaging and feedback rather than relying on passive drug release. X-ray, near-infrared and ultrasound-triggered platforms generate hydroxyl radicals or release paclitaxel for tumors, while MOFs and cobalt particles target inflammatory disease. Thioketal chemistry, oxygen vacancies and ROS-triggered hydrogel disassembly provide control over release and tissue barriers. Imaging-guided precision, safety and performance across cancer, cornea, bowel and kidney injury remain open questions.
9 papers · 26.5%
-
Redox Regulation Across Disease
Redox regulation is being linked to ferroptosis, metabolic disease, cancer drug resistance, inflammation and pain rather than treated as a single pathway. NRF2 activation, lipid and mitochondrial control, and NOX4/ROS/NLRP3 signaling recur alongside efforts to force ROS accumulation, as with p-coumaric acid or cryptotanshinone. HIF1α-KLF4-driven hemoglobin expression and EGFR/ROS signaling connect redox state to sorafenib resistance and glioma ferroptosis. The opposing use of antioxidants and pro-oxidant therapy leaves context-specific treatment selection unresolved.
8 papers · 23.5%
-
ROS-Based Cancer and Infection Therapy
ROS-generating nanomaterials are being developed to kill tumor cells and antibiotic-resistant bacteria while improving delivery through solid tissue. AIE photosensitizers and organelle-targeted systems couple ROS production to lysosomal autophagy, apoptosis, DNA damage, or broad-spectrum photodynamic killing. Combination effects include santamarine with cisplatin. Mitophagy-mediated ROS suppression emerges as a route to gemcitabine resistance, leaving selective activation and resistance control open.
7 papers · 20.6%
-
Antioxidant Nanotherapy for Oxidative Stress
Antioxidant nanotherapies are being tailored to restore redox balance in bone, joint, neural, pulmonary and neurodegenerative disease. Mn3O4 nanozymes, carbon-dot nanoreactors, peptide hydrogels and self-assembled fibers localize ROS scavenging or drug release to mitochondria, bone or injured tissue. The recurring aim is to reduce inflammation and oxidative damage while enabling regeneration, including neurite outgrowth and bone remodeling. Translation beyond localized preclinical disease remains open.
6 papers · 17.6%
-
Smart Therapy for Diabetic Wounds
Diabetic wound treatment is converging on responsive platforms that combine biofilm eradication with antioxidant and anti-inflammatory repair. Cross-linked hydrogels, chitosan microspheres and microneedle patches pair antibacterial or photodynamic action with modulation of the wound microenvironment. GSH scavenging and synthesis blockade strengthen photodynamic killing, while stage-specific delivery addresses changing wound biology. The direction is toward coordinated, sequential therapy rather than single-function dressings.
4 papers · 11.8%
In cancer, ROS scavenging can drive treatment resistance rather than protect against it
Hepatocellular carcinoma treated with sorafenib and gallbladder cancer made resistant to gemcitabine were each assumed to benefit from mechanisms that suppress damaging ROS, but the studies found that tumor-intrinsic ROS removal instead supported resistance: HIF1α–KLF4-induced extra-erythrocytic hemoglobin scavenged ROS and promoted sorafenib resistance in hepatocellular carcinoma 42744801Sep, while enhanced mitophagy maintained abnormally low ROS and drove gemcitabine resistance in gallbladder cancer 42716921Sep. Together, these findings recast ROS reduction from an unqualified protective strategy as a cancer-cell adaptation that can preserve malignant cells under therapy, making disruption of the scavenging or low-ROS state a potential treatment objective.
Papers
The 34 papers from the last 6 months that study reactive oxygen species directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
ROS-Responsive Nanomedicine (9)
- Ultrasmall Ag₂Se@Mn quantum dots enable dual-modal imaging-guided early detection and antioxidant therapy of acute kidney injury. Mikrochimica acta · 7 Sept 2026 PMID 42704498
- Multiphoton imaging-guided and feedback-enabled anti-inflammatory therapy over MOF nanoplatforms. Journal of materials chemistry. B · 1 Sept 2026 PMID 42676025
- ROS-Triggered Disassembly of Nanoparticle-Networked Hydrogels Enables Dynamic Gating of Corneal Tight Junctions. ACS applied materials & interfaces · 13 Aug 2026 PMID 42587441
- Nitric Oxide-Releasing Molecular Co-Assembly Enables Epithelial-Mesenchymal Transition Suppression and Intermolecular Electron Transfer-Enhanced Type-I Photodynamic Therapy. ACS nano · 11 Aug 2026 PMID 42579410
- Near-infrared light-triggered, self-amplifying targeted drug-delivery platform achieves precision treatment of retinoblastoma. International journal of pharmaceutics · 10 Jun 2026 PMID 42269794
- Oral Cobalt Coordination Microparticles for Targeted Inflammatory Bowel Disease Treatment. ACS applied bio materials · 9 Jun 2026 PMID 42263142
- Glutathione-Induced In Situ Oxygen Vacancies in FeOOH Nanospindles for Boosting Sonocatalytic Tumor Therapy. Angewandte Chemie (International ed. in English) · 9 Jun 2026 PMID 42261917
- IR783-enabled thioketal-bridged paclitaxel nanoprodrugs with ROS-responsive release for tumor imaging and chemotherapy. Journal of photochemistry and photobiology. B, Biology · 27 May 2026 PMID 42202709
- Long-Acting Dynamic Therapy Using X-Ray Activated Organic Nanoparticles for Afterglow Imaging Guided Deep Tumor Treatment. Angewandte Chemie (International ed. in English) · 23 May 2026 PMID 42175828
Redox Regulation Across Disease (8)
- Ursolic acid ameliorates metabolic dysfunction-associated fatty liver disease by regulating the NOX4/ROS/NLRP3 pathway. Naunyn-Schmiedeberg's archives of pharmacology · 5 Oct 2026 PMID 42834206
- HIF1α-KLF4 signaling dictates extra-erythrocyte expression of hemoglobin conferring sorafenib resistance in hepatocellular carcinoma. Signal transduction and targeted therapy · 15 Sept 2026 PMID 42744801
- p-Coumaric acid inhibits hepatocellular carcinoma through promoting ROS accumulation. Medical oncology (Northwood, London, England) · 10 Sept 2026 PMID 42720830
- Early high‑frequency spinal cord stimulation modulates the ROS/p38 MAPK/NF‑κB and CXCL10/CXCR3 pathways to alleviate neuropathic pain and promote spinal cord injury repair. International journal of molecular medicine · 14 Aug 2026 PMID 42596832
- Structure-Property Relationship Analysis of α-Keto Ester Prodrugs of Monomethyl Fumarate as NRF2 Activators. ACS chemical neuroscience · 7 Jul 2026 PMID 42412905
- Cryptotanshinone Targets Ferroptosis in Glioma via the EGFR/ROS Signaling Pathway. Neurochemical research · 25 Jun 2026 PMID 42348047
- Autophagy-ferroptosis crosstalk in sepsis: metabolic pathways, redox injury, and host-directed antioxidant nanomedicine. Frontiers in immunology · 12 Jun 2026 PMID 42282965
- A Lipid-Conjugation Strategy for Intracellular Reactive Oxygen Species Control in Hepatic Cells. Angewandte Chemie (International ed. in English) · 11 Jun 2026 PMID 42275385
ROS-Based Cancer and Infection Therapy (7)
- De Novo Design of Multi-Mechanistic AIE Photosensitizer for Broad-Spectrum Bacterial Eradication. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018578
- SUMOylated Reptin maintains low intracellular ROS levels by activating mitophagy to drive gemcitabine resistance in gallbladder cancer. Cell death & disease · 9 Sept 2026 PMID 42716921
- Intermolecular Noncovalent Locks Enable Red-Shifted Emission, Modulated Reactive Oxygen Species Generation Pathway, and Shuttle-Like Nanoassembly for Phototheranostics. ACS nano · 18 Aug 2026 PMID 42611238
- Lysosome-targeting naphthalimide-based AIEE nanoaggregates as a dual inducer of autophagy and apoptosis in cancer therapy. Nanoscale · 20 Jul 2026 PMID 42475021
- Mechanotherapeutic biomaterials: Overcoming physical barriers to enhance intratumoral drug delivery in solid tumours. Biomedical microdevices · 23 Jun 2026 PMID 42334617
- Santamarine Synergizes With Cisplatin via ROS/JNK Axis to Selectively Induce Apoptosis and DNA Damage in Oral Cancer Cells In Vitro. Drug development research · 26 May 2026 PMID 42187533
- Organelle-Targeted Photosensitizers for Enhanced Photodynamic Therapy of Cancer. Bioconjugate chemistry · 26 May 2026 PMID 42186767
Antioxidant Nanotherapy for Oxidative Stress (6)
- Mitochondria-targeted ROS-scavenging nanoreactor with dual-drug-loaded carbon dots for osteoarthritis therapy. Journal of materials chemistry. B · 15 Oct 2026 PMID 42876417
- Intrinsically Strain-Stiffening, Conductive, ROS-Scavenging Peptide-Polymer Hydrogel to Promote Neurite Outgrowth. Biomacromolecules · 14 Sept 2026 PMID 42734266
- Clioquinol-Loaded UiO-66(Ce) Metal-Organic Frameworks for Dual Reactive Oxygen Species Scavenging and Metal Chelation in Alzheimer's Disease. ACS applied bio materials · 17 Aug 2026 PMID 42606055
- Bone-targeted Mn3O4 nanozymes alleviate osteoporosis by remodeling the age-related oxidative stress microenvironment. Biomaterials science · 22 Jul 2026 PMID 42484352
- ROS produced in mitochondria entrapped by self-assembly peptide fibers for target therapy of glioma. Proceedings of the National Academy of Sciences of the United States of America · 15 Jul 2026 PMID 42455661
- Macrophage-amplified toxicity of indium tin oxide nanoparticles to bronchial epithelial cells involving ROS-associated NF-κB signaling. Toxicology · 27 May 2026 PMID 42203026
Smart Therapy for Diabetic Wounds (4)
- A dual-responsive nanosystem for synergistic antibacterial therapy and inflammatory microenvironment modulation in infected diabetic wound healing. Biomaterials science · 11 Aug 2026 PMID 42578380
- Multi-modular responsive hydroxypropyl chitosan-based hydrogel microspheres for stage-specific therapy in infected wounds. Carbohydrate polymers · 23 Jul 2026 PMID 42493128
- Nanoparticle-Cross-Linked Smart Responsive Hydrogels for Antimicrobial, Anti-Inflammatory, and Antioxidant Treatment of Diabetic Wounds. Biomacromolecules · 21 Jul 2026 PMID 42479468
- A GSH-scavenging and synthesis-blocking microneedle patch for augmenting photodynamic eradication of diabetic wound biofilms. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300219
By study type
Human data, design not indexed (2)
- A Lipid-Conjugation Strategy for Intracellular Reactive Oxygen Species Control in Hepatic Cells. Angewandte Chemie (International ed. in English) · 11 Jun 2026 PMID 42275385
- Glutathione-Induced In Situ Oxygen Vacancies in FeOOH Nanospindles for Boosting Sonocatalytic Tumor Therapy. Angewandte Chemie (International ed. in English) · 9 Jun 2026 PMID 42261917
Preclinical: animal, cell and lab studies (31)
- De Novo Design of Multi-Mechanistic AIE Photosensitizer for Broad-Spectrum Bacterial Eradication. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018578
- Mitochondria-targeted ROS-scavenging nanoreactor with dual-drug-loaded carbon dots for osteoarthritis therapy. Journal of materials chemistry. B · 15 Oct 2026 PMID 42876417
- HIF1α-KLF4 signaling dictates extra-erythrocyte expression of hemoglobin conferring sorafenib resistance in hepatocellular carcinoma. Signal transduction and targeted therapy · 15 Sept 2026 PMID 42744801
- Intrinsically Strain-Stiffening, Conductive, ROS-Scavenging Peptide-Polymer Hydrogel to Promote Neurite Outgrowth. Biomacromolecules · 14 Sept 2026 PMID 42734266
- p-Coumaric acid inhibits hepatocellular carcinoma through promoting ROS accumulation. Medical oncology (Northwood, London, England) · 10 Sept 2026 PMID 42720830
- SUMOylated Reptin maintains low intracellular ROS levels by activating mitophagy to drive gemcitabine resistance in gallbladder cancer. Cell death & disease · 9 Sept 2026 PMID 42716921
- Ultrasmall Ag₂Se@Mn quantum dots enable dual-modal imaging-guided early detection and antioxidant therapy of acute kidney injury. Mikrochimica acta · 7 Sept 2026 PMID 42704498
- Multiphoton imaging-guided and feedback-enabled anti-inflammatory therapy over MOF nanoplatforms. Journal of materials chemistry. B · 1 Sept 2026 PMID 42676025
- Intermolecular Noncovalent Locks Enable Red-Shifted Emission, Modulated Reactive Oxygen Species Generation Pathway, and Shuttle-Like Nanoassembly for Phototheranostics. ACS nano · 18 Aug 2026 PMID 42611238
- Clioquinol-Loaded UiO-66(Ce) Metal-Organic Frameworks for Dual Reactive Oxygen Species Scavenging and Metal Chelation in Alzheimer's Disease. ACS applied bio materials · 17 Aug 2026 PMID 42606055
- Early high‑frequency spinal cord stimulation modulates the ROS/p38 MAPK/NF‑κB and CXCL10/CXCR3 pathways to alleviate neuropathic pain and promote spinal cord injury repair. International journal of molecular medicine · 14 Aug 2026 PMID 42596832
- ROS-Triggered Disassembly of Nanoparticle-Networked Hydrogels Enables Dynamic Gating of Corneal Tight Junctions. ACS applied materials & interfaces · 13 Aug 2026 PMID 42587441
- Nitric Oxide-Releasing Molecular Co-Assembly Enables Epithelial-Mesenchymal Transition Suppression and Intermolecular Electron Transfer-Enhanced Type-I Photodynamic Therapy. ACS nano · 11 Aug 2026 PMID 42579410
- A dual-responsive nanosystem for synergistic antibacterial therapy and inflammatory microenvironment modulation in infected diabetic wound healing. Biomaterials science · 11 Aug 2026 PMID 42578380
- Multi-modular responsive hydroxypropyl chitosan-based hydrogel microspheres for stage-specific therapy in infected wounds. Carbohydrate polymers · 23 Jul 2026 PMID 42493128
- Bone-targeted Mn3O4 nanozymes alleviate osteoporosis by remodeling the age-related oxidative stress microenvironment. Biomaterials science · 22 Jul 2026 PMID 42484352
- Nanoparticle-Cross-Linked Smart Responsive Hydrogels for Antimicrobial, Anti-Inflammatory, and Antioxidant Treatment of Diabetic Wounds. Biomacromolecules · 21 Jul 2026 PMID 42479468
- Lysosome-targeting naphthalimide-based AIEE nanoaggregates as a dual inducer of autophagy and apoptosis in cancer therapy. Nanoscale · 20 Jul 2026 PMID 42475021
- ROS produced in mitochondria entrapped by self-assembly peptide fibers for target therapy of glioma. Proceedings of the National Academy of Sciences of the United States of America · 15 Jul 2026 PMID 42455661
- Structure-Property Relationship Analysis of α-Keto Ester Prodrugs of Monomethyl Fumarate as NRF2 Activators. ACS chemical neuroscience · 7 Jul 2026 PMID 42412905
- Cryptotanshinone Targets Ferroptosis in Glioma via the EGFR/ROS Signaling Pathway. Neurochemical research · 25 Jun 2026 PMID 42348047
- Mechanotherapeutic biomaterials: Overcoming physical barriers to enhance intratumoral drug delivery in solid tumours. Biomedical microdevices · 23 Jun 2026 PMID 42334617
- A GSH-scavenging and synthesis-blocking microneedle patch for augmenting photodynamic eradication of diabetic wound biofilms. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300219
- Autophagy-ferroptosis crosstalk in sepsis: metabolic pathways, redox injury, and host-directed antioxidant nanomedicine. Frontiers in immunology · 12 Jun 2026 PMID 42282965
- Near-infrared light-triggered, self-amplifying targeted drug-delivery platform achieves precision treatment of retinoblastoma. International journal of pharmaceutics · 10 Jun 2026 PMID 42269794
- Oral Cobalt Coordination Microparticles for Targeted Inflammatory Bowel Disease Treatment. ACS applied bio materials · 9 Jun 2026 PMID 42263142
- Macrophage-amplified toxicity of indium tin oxide nanoparticles to bronchial epithelial cells involving ROS-associated NF-κB signaling. Toxicology · 27 May 2026 PMID 42203026
- IR783-enabled thioketal-bridged paclitaxel nanoprodrugs with ROS-responsive release for tumor imaging and chemotherapy. Journal of photochemistry and photobiology. B, Biology · 27 May 2026 PMID 42202709
- Santamarine Synergizes With Cisplatin via ROS/JNK Axis to Selectively Induce Apoptosis and DNA Damage in Oral Cancer Cells In Vitro. Drug development research · 26 May 2026 PMID 42187533
- Organelle-Targeted Photosensitizers for Enhanced Photodynamic Therapy of Cancer. Bioconjugate chemistry · 26 May 2026 PMID 42186767
- Long-Acting Dynamic Therapy Using X-Ray Activated Organic Nanoparticles for Afterglow Imaging Guided Deep Tumor Treatment. Angewandte Chemie (International ed. in English) · 23 May 2026 PMID 42175828
Unclassified: not yet indexed with MeSH (1)
- Ursolic acid ameliorates metabolic dysfunction-associated fatty liver disease by regulating the NOX4/ROS/NLRP3 pathway. Naunyn-Schmiedeberg's archives of pharmacology · 5 Oct 2026 PMID 42834206
Written from 34 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-17 by GPT. Corrections: 2026-09-26 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.